Universal Beteiligungs und Servicegesellschaft mbH Makes New $717,000 Investment in Beam Therapeutics Inc. (NASDAQ:BEAM)

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH has invested approximately $717,000 in Beam Therapeutics, acquiring 36,707 shares of the company during the first quarter.
• Beam Therapeutics' stock price has seen a decline of 4.5%, with its market cap standing at $1.89 billion and recent earnings revealing a loss of ($1.24) EPS, missing analyst expectations.
• Despite recent challenges, Beam Therapeutics holds a consensus rating of "Buy" from analysts, with ten buy ratings and a target price averaging $48.75.

Universal Beteiligungs und Servicegesellschaft mbH bought a new position in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) during the first quarter, according to its most recent Form 13F filing with the SEC. The firm bought 36,707 shares of the company's stock, valued at approximately $717,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Northern Trust Corp raised its position in shares of Beam Therapeutics by 7.2% during the 4th quarter. Northern Trust Corp now owns 740,506 shares of the company's stock worth $18,365,000 after acquiring an additional 49,415 shares in the last quarter. GAMMA Investing LLC lifted its position in shares of Beam Therapeutics by 549.9% during the 1st quarter. GAMMA Investing LLC now owns 37,185 shares of the company's stock valued at $726,000 after acquiring an additional 31,463 shares during the period. Amalgamated Bank lifted its position in shares of Beam Therapeutics by 20.4% during the 1st quarter. Amalgamated Bank now owns 3,153 shares of the company's stock valued at $62,000 after acquiring an additional 534 shares during the period. Stifel Financial Corp boosted its position in Beam Therapeutics by 27.8% during the fourth quarter. Stifel Financial Corp now owns 13,662 shares of the company's stock worth $339,000 after purchasing an additional 2,976 shares in the last quarter. Finally, Rhumbline Advisers boosted its position in Beam Therapeutics by 11.9% during the first quarter. Rhumbline Advisers now owns 141,204 shares of the company's stock worth $2,758,000 after purchasing an additional 14,971 shares in the last quarter. 99.68% of the stock is owned by institutional investors and hedge funds.

Beam Therapeutics Stock Performance

Shares of NASDAQ:BEAM traded down $0.39 during midday trading on Wednesday, hitting $18.31. 1,161,085 shares of the stock were exchanged, compared to its average volume of 2,050,414. Beam Therapeutics Inc. has a 52-week low of $13.52 and a 52-week high of $35.25. The business's fifty day simple moving average is $18.74 and its two-hundred day simple moving average is $21.12. The company has a market capitalization of $1.84 billion, a PE ratio of -3.97 and a beta of 2.22.

Beam Therapeutics (NASDAQ:BEAM - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The company reported ($1.00) earnings per share for the quarter, beating analysts' consensus estimates of ($1.04) by $0.04. The company had revenue of $8.47 million for the quarter, compared to the consensus estimate of $13.29 million. Beam Therapeutics had a negative return on equity of 44.24% and a negative net margin of 609.24%. The company's quarterly revenue was down 28.0% on a year-over-year basis. During the same period in the previous year, the business earned ($1.11) earnings per share. As a group, equities analysts anticipate that Beam Therapeutics Inc. will post -4.57 EPS for the current year.

Insider Buying and Selling at Beam Therapeutics

In related news, insider Fmr Llc sold 48,374 shares of the business's stock in a transaction that occurred on Wednesday, July 30th. The shares were sold at an average price of $20.50, for a total value of $991,667.00. Following the completion of the transaction, the insider owned 2,073,665 shares in the company, valued at $42,510,132.50. The trade was a 2.28% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders have sold a total of 49,624 shares of company stock worth $1,015,628 over the last three months. Company insiders own 3.50% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the company. Cantor Fitzgerald raised Beam Therapeutics to a "strong-buy" rating in a research note on Monday, July 21st. Barclays cut their price objective on Beam Therapeutics from $25.00 to $21.00 and set an "equal weight" rating on the stock in a research note on Wednesday. Wells Fargo & Company cut their target price on shares of Beam Therapeutics from $75.00 to $70.00 and set an "overweight" rating on the stock in a report on Wednesday, May 7th. Finally, Guggenheim cut their target price on shares of Beam Therapeutics from $78.00 to $55.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. Two analysts have rated the stock with a hold rating, ten have assigned a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $48.42.

Beam Therapeutics Profile

Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.